UCB - Annual Gala Sponsor 2019

Author: BenCham Shanghai

 

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With around 7,500 people in 40 countries, the company generated revenue of €4.5 billion in 2017, and invested ~25% of revenue into research and development annually. UCB is listed on Euronext Brussels (symbol: UCB).


Since UCB’s creation in 1928, innovation and agile entrepreneurship have been in the company’s DNA. Throughout its 90-year journey, UCB has continuously been pushing the boundaries and has never shied away from making bold moves to reinvent itself. This innovation spirit and agility mindset is still UCB’s signatures today and will be for the future.


UCB started its pharmaceutical business operations in China in the early 90s. In 1996, UCB opened its first representative office in Shanghai. UCB leapfrogged to be a fast-growing biopharma company in China with the acquisition of Schwarz Pharma and its Zhuhai plant in 2006, as well as the successful launch of an anti-epileptic drug in the following year.


Head office located in Shanghai, UCB China also has regional offices in Beijing, Chengdu, Guangzhou, and a manufacturing site in Zhuhai. With more than 750 employees in China, the company has positively impacted the lives of millions of patients. In the recent years, UCB is making great efforts to bring more innovative products and solutions in immunology, neurology and bone health to create value for more Chinese patients.

UCB